d_risk Posted - 2 weeks ago

$MXCT - 10Q - Updated Risk Factors Evaluating a shift to Nasdaq-only listing could affect share liquidity, price, and investor accessibility for AIM-preferring investors. No substantial changes otherwise. https://d-risk.ai/MXCT/10-Q/2024-11-06

insiderbuyingselling Posted - 2 weeks ago

$MXCT new insider selling: 47689 shares. http://insiderbuyingselling.com/?t=MXCT

BioTuesdays Posted - 1 month ago

MaxCyte has appointed Ali Soleymannezhad as chief commercial officer, effective September 11, 2024 $MXCT https://biotuesdays.com/2024/10/10/maxcyte-appoints-ali-soleymannezhad-as-cco/

ReadyMate Posted - 1 month ago

@LineBacker04 $CAPR $SRPT Excellent posts but I do not agree with the $500m ‘typical valuation’. I’ve been in investing in biotechs since 1998 and have rarely seen such a mix of positive elements (stars aligned): derisking of the asset and clinical path forward (FDA guidance hugely lowers risk of a CRL); no competition in DMD and when cardio and skeletal hit the market, this is without question a multi-billion valuation: too often biotechs and the analysts project unrealistic market share as they underestimate competition … here we have blue skies ahead. Cash position: solid Trading potential: short squeeze as you explained … even more, shorters do no appreciate the fantastic setup they’ve achieved with P2/BLA filing etc and which will trigger large additional institutional interest (and buying pressure). Etc So I believe at this stage, a >1 bn valuation or $30+ is in the cards within a few weeks Go $CAPR , Go $CRDF , Go $MXCT (my top 3 for the next 6 months)

insiderbuyingselling Posted - 09/30/24

$MXCT new insider selling: 3000 shares. http://insiderbuyingselling.com/?t=MXCT

Stock_Titan Posted - 2 months ago

$MXCT MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases https://www.stocktitan.net/news/MXCT/max-cyte-signs-strategic-platform-license-with-kamau-therapeutics-to-mljbfyravias.html

Ed_Ng Posted - 2 months ago

$MXCT sell sell sell

KWalzz Posted - 08/23/24

$MXCT good setup, thinking about taking profit here today ... if so will come back for sure ...

epsguid Posted - 3 months ago

$MXCT reported a loss of $0.09, consensus was ($0.14) via @eWhispers #epsbeat http://eps.sh/d/mxct

Cjohn224 Posted - 3 months ago

$MXCT quite a good report imo. Strong margins (87%) with big rev beat. Back to $5 (at minimum), good things ahead with SPL & CGT growth.

Stock_Titan Posted - 3 months ago

$MXCT MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance https://www.stocktitan.net/news/MXCT/max-cyte-reports-second-quarter-and-half-year-2024-financial-results-di9p2p867kzv.html

NVDAMillionaire Posted - 07/31/24

$MXCT MaxCyte (MXCT) Poised for Continued Growth as Cell Therapy Market Expands http://beyondspx.com/2024/07/31/maxcyte-mxct-poised-for-continued-growth-as-cell-therapy-market-expands/

insiderbuyingselling Posted - 4 months ago

$MXCT new insider selling: 33333 shares. http://insiderbuyingselling.com/?t=MXCT

Stock_Titan Posted - 4 months ago

$MXCT MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024 https://www.stocktitan.net/news/MXCT/max-cyte-to-report-second-quarter-2024-financial-results-on-august-6-i2c8rm1ptcf9.html

Brian001 Posted - 06/24/24

$MXCT my avg is $5.2 do you think it will get there.

RichSaunder Posted - 5 months ago

$CLPT $MXCT $SRPT Good news for rare disease patients. FDA needs to understand the importance of cell and gene therapies moving forward.

CEOBuysDisclosures Posted - 5 months ago

$MXCT CEO purchased 100,000 shares at $4.89 for a total of $489,066. Masoud Maher now owns 100,000 shares. https://ceo-buys.com

InsiderPeek Posted - 5 months ago

$MXCT CEO Masoud Maher bought 100k shares for $489.1k (ownership up Inf%) insiderpeek.com/company/MXCT

Stock_Titan Posted - 6 months ago

$MXCT MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development https://www.stocktitan.net/news/MXCT/max-cyte-signs-strategic-platform-license-agreement-with-legend-nn3ojkp5recm.html

valueforme Posted - 6 months ago

$MXCT Listened to the Cowen conf Q&A, did some initial DD. Looks like a good stock to bet on ex-vivo cell therapies & gene editing without being exposed to the risks of a single biotech company's pipeline

frogoracletrading Posted - 6 months ago

$MXCT Support / Resistance Levels Here are the levels to watch after the sharp move up. Larger Image: https://s3.tradingview.com/snapshots/c/CG1mPmie.png

Bigeyes2 Posted - 6 months ago

$MXCT swing

epsguid Posted - 6 months ago

$MXCT reported a loss of $0.09, consensus was ($0.14) via @eWhispers #epsbeat http://eps.sh/d/mxct

Stock_Titan Posted - 6 months ago

$MXCT MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance https://www.stocktitan.net/news/MXCT/max-cyte-reports-first-quarter-2024-financial-results-and-updates-4u8q61d7kquu.html

Stock_Titan Posted - 7 months ago

$MXCT MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 https://www.stocktitan.net/news/MXCT/max-cyte-to-report-first-quarter-2024-financial-results-on-may-7-p3o1b1hpbxki.html

Stock_Titan Posted - 7 months ago

$MXCT MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) https://www.stocktitan.net/news/MXCT/max-cyte-signs-strategic-platform-license-with-be-biopharma-to-1kpolj7wlcnv.html

AnaChart Posted - 8 months ago

$MXCT https://anachart.com/wp-content/uploads/ana_temp/1710360123_soc-img.jpg

DonCorleone77 Posted - 8 months ago

$MXCT MaxCyte affirms FY24 guidance The company states: "Management is reiterating 2024 revenue guidance for core business revenue and SPL Program-related revenue. Management expects full year 2024 core business revenue to be flat to 5% growth compared to 2023, and SPL Program-related revenue is expected to be approximately $3 million. Our outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR's CASGEVYTM and reflects a difficult year-over-year comparison from a client milestone recognized in 2023 that was initially expected in 2024. Management expects to end 2024 with $175 million in total cash, cash equivalents and investments."

DonCorleone77 Posted - 8 months ago

$MXCT MaxCyte reports Q4 EPS (5c), consensus (7c) Reports Q4 revenue $15.7M, consensus $13.1M. "In 2023, we navigated a challenging operating environment in our industry, that included increased capital conservatism and pipeline portfolio reevaluation among our customers. Our team adapted well to the changing environment last year, and I am confident in our ability to execute across the business this year," said Maher Masoud, President and CEO of MaxCyte. "We are pleased with our accomplishments and progress in 2023, which included supporting the recent FDA approval of CASGEVYTM by our client, Vertex Pharmaceuticals. MaxCyte signed five new SPLs in 2023 and we have seen continued momentum with three additional SPLs signed in January 2024. Our pipeline of potential clients remains robust, and we look forward to further expanding our portfolio of SPLs in 2024. The opportunity in front of us in the cell therapy industry continues to strengthen, and we will focus on executing in 2024...

epsguid Posted - 8 months ago

$MXCT reported a loss of $0.05, consensus was ($0.10) via @eWhispers #epsbeat http://eps.sh/d/mxct